ArticleImmunity2024
Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants.
Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 73 citations in OpenAlex.
- Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19.The Journal of infectious diseases · 2026Trial
- Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.Journal of virology · 2026Article
- Article
- Potent type-specific de novo antibodies complement broadly reactive imprinted antibodies in immune responses to SARS-CoV-2 variants.Nature immunology · 2026Article
- Pre-vaccine sentinel antibodies predict blunted vaccine responses.Cell press blue · 2026Article
- Variant-specific and cross-reactive antibody responses following COVID-19 booster vaccinations and SARS-CoV-2 breakthrough infections.Scientific reports · 2026Article
- Evaluating Memory B Cell Cross-Reactivity Between Ancestral and Future SARS-CoV-2 Variants-Evidence for Original Antigenic Sin.Vaccines · 2026Article
- Clade 2.3.4.4b H5N1 influenza virus and SARS-CoV-2 seroprevalence among owned and feral cats in Philadelphia and surrounding communities.bioRxiv : the preprint server for biology · 2026Article
- SARS-CoV-2 Omicron infection reveals imprinted antibody responses in the absence of vaccination.iScience · 2026Article
- Optimizing mouse models for mRNA vaccines: addressing dose translation challenges.Scientific reports · 2026Article
- Article
- Repeated COVID-19 vaccine boosters elicit variant-specific memory B cells in humans.Cell reports · 2026Article
- Impact of adjuvants on a recombinant SARS-CoV-2 spike vaccine: Protective efficacy and recall antibody response following homologous challenge.Biosafety and health · 2026Article
- Humoral epitope dominance and immune imprinting by SARS-CoV-1 and SARS-CoV-2 vaccines.Immunology and cell biology · 2026Article
- Article
- Article
- Maternal immunization status and SARS-CoV-2 antibody transfer to neonates at birth.Frontiers in pediatrics · 2026Article
- Evaluation of pre-Omicron population immunity for SARS-CoV-2 in the Household Influenza Vaccine Evaluation (HIVE) cohort.PloS one · 2026Article
- Comparative analysis of immune escape and BCR repertoire remodeling after Omicron BF.7 and JN.1 infections.Frontiers in immunology · 2026Article
- SARS-CoV-2 variants: biology, pathogenicity, immunity and control.Nature reviews. Microbiology · 2026Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
The spike glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to accumulate substitutions, leading to breakthrough infections of vaccinated individuals. It remains unclear if exposures to antigenically distant SARS-CoV-2 variants can overcome memory B cell biases established by initial SARS-CoV-2 encounters. We determined the specificity and functionality of antibody and B cell responses following exposure to BA.5 and XBB variants in individuals who received ancestral SARS-CoV-2 mRNA vaccines. BA.5 exposures elicited antibody responses that targeted epitopes conserved between the BA.5 and ancestral spike. XBB exposures also elicited antibody responses that primarily targeted epitopes conserved between the XBB.1.5 and ancestral spike. However, unlike BA.5, a single XBB exposure elicited low frequencies of XBB.1.5-specific antibodies and B cells in some individuals. Pre-existing cross-reactive B cells and antibodies were correlated with stronger overall responses to XBB but weaker XBB-specific responses, suggesting that baseline immunity influences the activation of variant-specific SARS-CoV-2 responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.